InterCure Teams Up With TYSON 2.0 In Israel, Australia, United Kingdom, Germany And Other EU Countries

InterCure Ltd. INCR INCR INCR (dba Canndoc) and TYSON 2.0 have entered into a binding letter of intent for a business partnership.

The partnership will see InterCure granted an exclusive distribution license to cultivate, manufacture, sell, market, and distribute all approved products and brands of TYSON 2.0 in Israel, Australia, United Kingdom, Germany and other EU countries such as Switzerland. InterCure will also have the right to use the name, the marks and the TYSON 2.0 intellectual property in these territories.

“My vision for TYSON 2.0 has been to share high-quality cannabis that has saved my life with my fans and people wherever they may be. This relationship with InterCure is the next step of scaling up our operations to deliver on that vision. Together, TYSON 2.0 and InterCure will provide immediate solutions to international communities looking for the high-quality cannabis flower, concentrates and consumables that TYSON 2.0 is known for,” stated Mike Tyson, chief brand officer of TYSON 2.0.

Alexander Rabinovitch, CEO of InterCure, stated: "This strategic partnership is an exciting opportunity for us to expand our presence and offerings in key international markets. TYSON 2.0's innovative products and reputation for purity and precision makes them the perfect partner for us as we continue to grow our business."

Photo: Benzinga edit with photos by jarmoluk and lindsayfox on Pixabay

Related News

InterCure Shares Soar On FY22 Record Revenue Of $108.3M

InterCure Sues Cann Pharmaceuticals To Recover Funds Following Failed Merger

InterCure Teams Up Wit Praetorian Global To License, Manufacture And Distribute Cannabis Brand 'Binske'